...
首页> 外文期刊>International Journal of Cancer =: Journal International du Cancer >Quantitative monitoring of cyclin D1 expression: A molecular marker for minimal residual disease monitoring and a predictor of the disease outcome in patients with mantle cell lymphoma.
【24h】

Quantitative monitoring of cyclin D1 expression: A molecular marker for minimal residual disease monitoring and a predictor of the disease outcome in patients with mantle cell lymphoma.

机译:定量监测细胞周期蛋白D1的表达:用于监测最小残留疾病的分子标记物,以及套细胞淋巴瘤患者疾病预后的预测因子。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

In mantle cell lymphoma (MCL), minimal residual disease (MRD) is an indicator of the disease outcome. Quantitative methods used so far do not provide a suitable molecular marker in 30-70% patients with MCL (depending on the technique used). We tested cyclin D1 as a marker for quantitative MRD monitoring. The real-time PCR of cyclin D1 mRNA was performed in 144 bone marrow (BM) specimens including 95 BMs from MCL patients, 39 BMs from patients with other B-cell non-Hodgkin's lymphomas and 10 BMs from healthy volunteer donors. In 73 BMs obtained from 20 MCL patients we examined the cyclin D1 level during the treatment and follow-up period. We detected a cyclin D1 overexpression exclusively in BMs infiltrated with MCL, including minimal residual infiltration. Dynamics of cyclin D1 correlated with the patient's clinical status in 69/73 BMs. Individual monitoring of patients during the disease course showed cyclin D1 quantitative changes accompanying either the disease relapse or a successful treatment response or the disease-free survival (remission) and it showed a predictive significance. Cyclin D1 detection is a promising approach for the quantitative MRD monitoring in MCL patients, and the individual monitoring of the cyclin D1 dynamics represents a suitable indicator of the disease course. (c) 2008 Wiley-Liss, Inc.
机译:在套细胞淋巴瘤(MCL)中,最小残留疾病(MRD)是疾病预后的指标。迄今为止,在30-70%的MCL患者中,定量方法尚不能提供合适的分子标记物(取决于所使用的技术)。我们测试了细胞周期蛋白D1作为定量MRD监测的标志物。细胞周期蛋白D1 mRNA的实时PCR在144个骨髓(BM)标本中进行,其中包括来自MCL患者的95 BM,来自其他B细胞非霍奇金淋巴瘤患者的39 BM和来自健康志愿者供体的10 BM。在从20名MCL患者中获得的73例BMs中,我们检查了治疗和随访期间细胞周期蛋白D1的水平。我们检测到细胞周期蛋白D1过表达仅在MCL浸润的BMs中表达,包括最小的残留浸润。在69/73 BMs中,细胞周期蛋白D1的动态与患者的临床状况相关。在疾病过程中对患者进行的单独监测显示,细胞周期蛋白D1的定量变化伴随疾病复发或成功的治疗反应或无病生存(缓解),并显示出预测意义。细胞周期蛋白D1检测是MCL患者定量MRD监测的一种有前途的方法,细胞周期蛋白D1动态的个体监测代表了疾病进程的合适指标。 (c)2008 Wiley-Liss,Inc.

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号